Douglass Given - Arrowhead Pharmaceuticals Director
| ARWR Stock | USD 23.13 1.01 4.57% |
Director
Dr. Douglass B. Given is the Chairman of the Board and Director of Arrowhead Pharmaceuticals Inc. He was a director of the Company since 2010. Doug is Managing Partner at Health2047 Capital Partners LLC. He served as Health2047 Inc.s Chief Executive from its founding in August of 2015 until January 2018. Previously, Doug spent more than a decade in VC as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sectorspecific funds he was associated with the partnership from 19992015. A physician and medical scientist by background, Doug was a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt and a serial entrepreneur, as well as a VCist. In addition to a number of private companies, he led three public biotechnology and biopharmaceutical companies as CEO. Doug has served on more than 20 public and private boards. He is currently a Director at Health2047 Inc., board Chair at Akiri Inc., Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc. and Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Stanford Institute for Economic Policy Research, and The Houston Methodist Research Institute. since 2013.
| Age | 65 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 |
| Phone | 626 304 3400 |
| Web | https://arrowheadpharma.com |
Arrowhead Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2466) % which means that it has lost $0.2466 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0624) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/30/2024, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 04/30/2024, Non Current Assets Total is likely to grow to about 790.5 M, while Other Assets are likely to drop slightly above 229.4 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Timothy Shannon | CytomX Therapeutics | 56 | |
| Joseph Wender | Ionis Pharmaceuticals | 73 | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Mark Goldberg | Blueprint Medicines Corp | 63 | |
| John Scarlett | CytomX Therapeutics | 67 | |
| Joseph Klein | Ionis Pharmaceuticals | 56 | |
| Matthew Young | CytomX Therapeutics | 49 | |
| Paul Friedman | Incyte | 75 | |
| Peter Kolchinsky | Wave Life Sciences | 41 | |
| Myron Holubiak | Assembly Biosciences | 70 | |
| Elizabeth Anderson | Biomarin Pharmaceutical | N/A | |
| Anthony Altig | Assembly Biosciences | 61 | |
| Ken Takanashi | Wave Life Sciences | 54 | |
| Takeshi Wada | Wave Life Sciences | 54 | |
| Michael Grey | Biomarin Pharmaceutical | 65 | |
| Alan Lewis | Assembly Biosciences | 71 | |
| Joseph Loscalzo | Ionis Pharmaceuticals | 66 | |
| Wendy Dixon | Incyte | 62 | |
| Masaharu Tanaka | Wave Life Sciences | 61 | |
| Dennis Slamon | Biomarin Pharmaceutical | 68 | |
| Charles Rowland | Blueprint Medicines Corp | 59 | |
Management Performance
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.25 |
Arrowhead Pharmaceuticals Leadership Team
Elected by the shareholders, the Arrowhead Pharmaceuticals' board of directors comprises two types of representatives: Arrowhead Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arrowhead. The board's role is to monitor Arrowhead Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arrowhead Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arrowhead Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Douglas Given, Chairman of the Board | ||
| Javier MD, Chief Officer | ||
| Charles McKenney, Independent Director | ||
| Zhen Li, Senior Vice President - Chemistry & Manufacturing | ||
| Vince Anzalone, IR Contact Officer | ||
| MBA MD, Chief Medicine | ||
| Michael Perry, Independent Director | ||
| Chad Rubin, IR Contact Officer | ||
| Tracie Oliver, Chief Officer | ||
| PharmD JD, COO Counsel | ||
| Nadia MBA, VP Treasurer | ||
| Patrick OBrien, General Counsel | ||
| William Waddill, Independent Director | ||
| Howard Lovy, Director Communications | ||
| Kenneth Myszkowski, Chief Officer | ||
| Susan Boynton, Vice President - Regulatory Affairs | ||
| Edward Frykman, Director, Chairman of Audit Committee, Member of Nomination Committee, Member of Compensation Committee, Director of Insert Therapeutics Inc, Director of Unidym, Director of Aonex and Director of Calando | ||
| Bruce MD, Chief Scientist | ||
| Vincent CFA, Head VP | ||
| Douglass Given, Director | ||
| Aaron Tan, Head Tax | ||
| Peter Leone, Vice President-Strategy & Program Management | ||
| Bruce Given, COO | ||
| Christopher Anzalone, CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics | ||
| Mauro Ferrari, Scientific Advisor, Director, Member of Nomination Committee and Member of Compensation Committee | ||
| Mark Davis, Founder Calando | ||
| David Lewis, Chief Scientific Officer | ||
| Mark Seefeld, Head VP |
Arrowhead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arrowhead Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (1.63) % | ||||
| Operating Margin | (38.45) % | ||||
| Current Valuation | 3.06 B | ||||
| Shares Outstanding | 123.9 M | ||||
| Shares Owned By Insiders | 4.40 % | ||||
| Shares Owned By Institutions | 67.24 % | ||||
| Number Of Shares Shorted | 8.87 M | ||||
| Price To Earning | 482.39 X |
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Arrowhead Stock
| 0.87 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.75 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.66 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Arrowhead Stock
| 0.79 | ACB | Aurora Cannabis Downward Rally | PairCorr |
| 0.76 | HCM | HUTCHMED DRC | PairCorr |
| 0.71 | CGC | Canopy Growth Corp Downward Rally | PairCorr |
| 0.59 | FLGC | Flora Growth Corp Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.098 | Earnings Share (2.77) | Revenue Per Share 1.697 | Quarterly Revenue Growth (0.94) | Return On Assets (0.25) |
The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.